BEYFORTUS 50mg/ml (Nirsevimab PFS) 50mg/ml

Beyfortus 50mg/ml (nirsevimab) is a prescription monoclonal antibody used to protect infants from respiratory syncytial virus (RSV). This ready-to-use prefilled syringe offers a convenient single-dose option for RSV prevention. Store between 2–8°C to maintain potency. Always consult a healthcare provider before use.

Strength

50mg/ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Sanofi Pasteur Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Beyfortus 50mg/ml is used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants. It is designed for infants born during or entering their first RSV season, as well as high-risk infants up to 24 months of age. Parents often ask, 'What is nirsevimab used for?'—it provides passive immunity against RSV infection.

Side Effects

Nirsevimab works by providing antibodies that help the immune system fight RSV. Most infants experience no noticeable effects after administration, though some may briefly feel mild discomfort at the injection site. Parents may observe temporary fussiness or low-grade fever in the first day or two after receiving the dose.

Precautions & Warnings

Keep Beyfortus refrigerated between 2–8°C and protect it from light. Do not freeze or shake the prefilled syringe. Before use, inspect the liquid for particles or discoloration; discard if either is present. Always follow healthcare provider instructions for proper handling and administration.

Avoid Interactions

Limited data exist on drug interactions with nirsevimab, as it is a monoclonal antibody. No known interactions with vaccines or common medications have been reported. However, always inform your healthcare provider about all medications and vaccines your infant is receiving before administration.

Frequently Asked Questions

Beyfortus 50mg/ml is used to prevent respiratory syncytial virus (RSV) infection in infants during their first RSV season.

It is given as a single intramuscular injection by a healthcare professional.

Yes, it can be administered alongside routine childhood vaccines, but consult your pediatrician first.

Common side effects may include mild pain at the injection site or temporary fussiness.

Store between 2–8°C and protect from light; do not freeze or shake the prefilled syringe.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.